TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34930099

Group type: EXPERIMENTAL
Intervention: Messages about COVID‐19 risk
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Messages about smoking risk
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Combined COVID‐19 and smoking risk messages
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: SPD presence
Number of subjects: 1004
Study: 32228532

Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based intervention and motivational interviewing
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 110
Study: 33849608

Group type: EXPERIMENTAL
Intervention: Once weekly selinexor (100 mg), once weekly bortezomib (1.3 mg/m2), and 40 mg per week dexamethasone (XVd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard twice weekly bortezomib and 80 mg per week dexamethasone (Vd)
Number of subjects: 0
Study: 33322129

Group type: COMPARATOR
Intervention: Placebo (PLAC) - told they would receive 6 mg/kg of caffeine but received a placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (CONT) - no substance given
Number of subjects: 13
Study: 36180567

Group type: COMPARATOR
Intervention: Single-layer modified Kugel mesh in the preperitoneal space
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Optional onlay mesh in the inguinal canal with preperitoneal mesh placement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (1-layer and 2-layer)
Number of subjects: 50
Study: 33449078

Group type: EXPERIMENTAL
Intervention: EUD (euhydrated arrival plus no fluid)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EUR (euhydrated arrival plus fluid replacement)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: HYD (hypohydrated arrival plus no fluid)
Number of subjects: 23
Study: 32381429

Group type: EXPERIMENTAL
Intervention: Transcriptome analysis of clinical psoriatic samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPAR‐fatty acids metabolism pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural‐hormone regulation pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian entrainment pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological immunofluorescence staining
Number of subjects: 0
Study: 33941080

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg subcutaneous injection monthly with a loading dose of 240 mg
Number of subjects: 163
Study: 35448950

Group type: COMPARATOR
Intervention: Etomidate 0.2 mg/kg IV followed by etomidate 0.05 mg/kg IV (group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg IV, then etomidate 0.1 mg/kg IV, followed by etomidate 0.05 mg/kg IV (group KE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Etomidate (group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine and etomidate (group KE)
Number of subjects: 60
Study: 34642756

Group type: EXPERIMENTAL
Intervention: 1 cup (1CB, 180 g) of canned beans
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ½ cup (½CB, 90 g) of canned beans
Number of subjects: 73

Group type: COMPARATOR
Intervention: White rice (WR) control
Number of subjects: 73
Study: 32800653

Group type: EXPERIMENTAL
Intervention: Ensure Plus with Zenpep (75,000 USP lipase units)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ensure Plus alone
Number of subjects: 17
Study: 36141875

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 18
Study: 33845888

Group type: EXPERIMENTAL
Intervention: Craniotomy without dural tenting sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Craniotomy with dural tenting sutures
Number of subjects: 0
Study: 32723679

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fosbretabulin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 107
Study: 36069189

Group type: EXPERIMENTAL
Intervention: Computational mapping system using 12-lead ECG data
Number of subjects: 225
Study: 34982716

Group type: EXPERIMENTAL
Intervention: Mobile Link intervention (automated twice-weekly SMS and voice messages)
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Control group (existing standard care including free HIV and STI counseling and testing)
Number of subjects: 1118
Study: 32700396

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aspirin 100 mg/d
Number of subjects: 50
Study: 35712855

Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bedtime restriction therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition (time in bed regularisation)
Number of subjects: 61
Study: 33939629

Group type: EXPERIMENTAL
Intervention: Antischistosomal mass drug administration (MDA) with praziquantel
Number of subjects: 200000
Study: 32522251

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w
Number of subjects: 2108

Group type: EXPERIMENTAL
Intervention: Sarilumab 150/200 mg q2w + csDMARDs
Number of subjects: 2108

Group type: COMPARATOR
Intervention: Placebo + csDMARDs
Number of subjects: 2108

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 2108
Study: 33932949

Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction (Group II: 32 patients)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Isolated ACL reconstruction (Group I: 25 patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction
Number of subjects: 57
Study: 34433305

Group type: EXPERIMENTAL
Intervention: MRI-based thrombolysis with alteplase
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 32973176

Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA) 45 mg/m2 orally, days 1–15/cycle in combination with gemcitabine-nab-paclitaxel chemotherapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: gemcitabine-nab-paclitaxel chemotherapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 27
Study: 36056421

Group type: EXPERIMENTAL
Intervention: Rib fixation and standard pain medication
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard pain medication alone
Number of subjects: 102
Study: 34749675

Group type: EXPERIMENTAL
Intervention: Participant Engagement Activities (PEAs)
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Attendance at multiple PEAs
Number of subjects: 2629
Study: 35144700

Group type: COMPARATOR
Intervention: 4‐year EI
Number of subjects: 360

Group type: COMPARATOR
Intervention: 2‐year EI
Number of subjects: 360
Study: 35607896

Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI) training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Active control condition (pro-environmental training)
Number of subjects: 68
Study: 32170451

Group type: EXPERIMENTAL
Intervention: cONS (2.4 kcal/ml, 125 ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: sONS (1.5 kcal/ml, 200 ml)
Number of subjects: 51
Study: 36403158

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin plus gentamicin (arm B)
Number of subjects: 7617

Group type: COMPARATOR
Intervention: Procaine benzylpenicillin and gentamicin (arm C)
Number of subjects: 7617
Study: 33692429

Group type: EXPERIMENTAL
Intervention: High salinity treatment (300-500 mM NaCl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomly selected genes of important pathways
Number of subjects: 0
Study: 32237331

Group type: EXPERIMENTAL
Intervention: Huangqin Qingre Chubi Capsules (HQC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Salazosulfapyridine (SASP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (30 healthy people)
Number of subjects: 58
Study: 36187125

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with meibomian gland expression (MGX)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Instant warm compresses combined with MGX (physiotherapy group)
Number of subjects: 13
Study: 33958525

Group type: EXPERIMENTAL
Intervention: Radicular cysts (RCs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Residual radicular cysts
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intense inflammatory infiltrate
Number of subjects: 60
Study: 32794023

Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (15%) for 14 days
Number of subjects: 10
Study: 35486840

Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia Training (IHT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 32841475

Group type: EXPERIMENTAL
Intervention: 100 mm NaCl
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: >50 mm NaCl
Number of subjects: 5
Study: 35148736

Group type: EXPERIMENTAL
Intervention: Intravenous TXA 20 mg/kg preoperatively, followed by 10 mg/kg at 3 and 6 hours postoperatively, and gauze soaked with TXA for 10 minutes before incision closure
Number of subjects: 49
Study: 33487528

Group type: COMPARATOR
Intervention: Screening only (Control)
Number of subjects: 2571

Group type: EXPERIMENTAL
Intervention: PFBA (Personalised Feedback and Brief Advice)
Number of subjects: 2571

Group type: EXPERIMENTAL
Intervention: PFBA plus eBI (electronic brief intervention)
Number of subjects: 2571
Study: 35608683

Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Clinpro Sealant, 3 M ESPE, MN, USA) plus adhesive (Single Bond Universal, 3 M ESPE, MN, USA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flowable resin (Filtek Flow Z350XT, 3 M ESPE, MN, USA) plus adhesive (Single Bond Universal, 3 M ESPE, MN, USA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no repair treatment)
Number of subjects: 54
Study: 33504932

Group type: EXPERIMENTAL
Intervention: Attribution theory-based online video intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Positive control video
Number of subjects: 147

Group type: COMPARATOR
Intervention: Negative control video
Number of subjects: 147
Study: 33087584

Group type: COMPARATOR
Intervention: Standard conscious sedation (SCS) including opiates and/or benzodiazepines pre-ICA
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Music plus opiates and/or benzodiazepines as needed
Number of subjects: 72
Study: 35150651

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 0
Study: 34074879

Group type: EXPERIMENTAL
Intervention: Preemptive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMV cell-mediated immune assays
Number of subjects: 0
Study: 34853185

Group type: EXPERIMENTAL
Intervention: One session of stage‐of‐change‐based physical activity education and counseling plus written educational material
Number of subjects: 35

Group type: COMPARATOR
Intervention: Written educational material alone
Number of subjects: 35
Study: 35988568

Group type: EXPERIMENTAL
Intervention: Half-dose betamethasone (11·4 mg)
Number of subjects: 3141

Group type: COMPARATOR
Intervention: Full-dose betamethasone (11·4 mg)
Number of subjects: 3141
Study: 33369763

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard fractionation (SF)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tumors with strong expression of EpCAM
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tumors without strong expression of EpCAM
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: p53 and p16 status
Number of subjects: 88
Study: 32950115

Group type: EXPERIMENTAL
Intervention: Nurse-led physical activity intervention (outdoor group walking, 5 days a week for 12 weeks, 40 minutes each session)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 34505395

Group type: EXPERIMENTAL
Intervention: Early outcome data analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early outcome data as a surrogate
Number of subjects: 0
Study: 34022073

Group type: EXPERIMENTAL
Intervention: Topical formulations containing cannabidiol (CBD) and palmitoylethanolamide (PEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemp seed oil product
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannabinoid products (CBD, PEA, and hemp seed oil formulations)
Number of subjects: 0
Study: 36184061

Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 115

Group type: COMPARATOR
Intervention: ILR monitoring
Number of subjects: 115
Study: 33260376

Group type: EXPERIMENTAL
Intervention: CIT/HOMO/VITE (citicoline 500 mg, homotaurine 50 mg, vitamin E 12 mg) in addition to current topical therapy for 4 months.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Current topical therapy alone for 4 months (after CIT/HOMO/VITE treatment).
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Current topical therapy for 4 months followed by CIT/HOMO/VITE for 4 months.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: CIT/HOMO/VITE in addition to current topical therapy for 4 months followed by topical therapy alone for 4 months.
Number of subjects: 109
Study: 34737786

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention combined with conventional medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medication alone
Number of subjects: 0
Study: 32371199

Group type: EXPERIMENTAL
Intervention: Continuous monitoring data (pre-ablation)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Clinical assessment (pre-ablation)
Number of subjects: 346
Study: 35876757

Group type: COMPARATOR
Intervention: Standard Malleable Stylet (SMS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pediatric Rigid Stylet (PRS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tracheal Tube Introducer (TTI)
Number of subjects: 51
Study: 34433441

Group type: EXPERIMENTAL
Intervention: Anticipatory care planning (ACP) intervention
Number of subjects: 16
Study: 33253237

Group type: EXPERIMENTAL
Intervention: Adaptive treatment (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-adaptive control (n = 20)
Number of subjects: 40
Study: 35377244

Group type: EXPERIMENTAL
Intervention: 40 mg of undenatured collagen daily for 24 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 96
Study: 32299108

Group type: EXPERIMENTAL
Intervention: Combined Foley balloon and misoprostol (PGE1)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Misoprostol (PGE1) alone
Number of subjects: 236
Study: 36182743

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) applied to fathers and newborns
Number of subjects: 60

Group type: COMPARATOR
Intervention: No kangaroo care (control group)
Number of subjects: 60
Study: 33689635

Group type: EXPERIMENTAL
Intervention: Near optical correction containing base-in prism
Number of subjects: 64

Group type: COMPARATOR
Intervention: Near optical correction (placebo)
Number of subjects: 64
Study: 32414347

Group type: EXPERIMENTAL
Intervention: Self-directed physical activity program with motivational interviewing (MI) for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Self-directed physical activity program without motivational interviewing (delayed intervention)
Number of subjects: 64
Study: 35575069

Group type: EXPERIMENTAL
Intervention: MI‐MOPs
Number of subjects: 33

Group type: COMPARATOR
Intervention: non‐MI‐MOPs
Number of subjects: 33
Study: 33721201

Group type: EXPERIMENTAL
Intervention: High-stakes assessment (assessment would affect the resident’s progress)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Low-stakes assessment (assessment would not affect the resident’s progress)
Number of subjects: 158
Study: 32640196

Group type: EXPERIMENTAL
Intervention: Multimodal telemonitoring for 6 months
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 206
Study: 35764027

Group type: EXPERIMENTAL
Intervention: WhatsApp Reinforced Education (WRE)
Number of subjects: 685

Group type: COMPARATOR
Intervention: No Reinforced Education (NRE)
Number of subjects: 685
Study: 32907521

Group type: EXPERIMENTAL
Intervention: Telemedicine group (in-hospital medication evaluation, drug reorganization, medical monitoring, and advice via telemedicine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 32524948

Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day course)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35856170

Group type: EXPERIMENTAL
Intervention: Program to Enhance Adjustment to Residential Living (PEARL)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 219
Study: 32997386

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed following RTI-related GP consultation
Number of subjects: 992

Group type: COMPARATOR
Intervention: No antibiotics (control)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed for infants with DS
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed for older children with DS
Number of subjects: 992
Study: 35599514

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 84
Study: 33300578

Group type: EXPERIMENTAL
Intervention: 80 mg Silexan
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 640 mg Silexan
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2 mg lorazepam (active control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 mg lorazepam (active control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32205026

Group type: EXPERIMENTAL
Intervention: Audiovisual action observation training (AAO) with rhythmic auditory stimulation and physical training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Visual action observation training (VAO) with physical training
Number of subjects: 30
Study: 35318122

Group type: EXPERIMENTAL
Intervention: 40 Hz ON-tACS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: active ON-tDCS
Number of subjects: 85

Group type: COMPARATOR
Intervention: sham ON-tDCS
Number of subjects: 85

Group type: COMPARATOR
Intervention: 1 Hz ON-tACS
Number of subjects: 85
Study: 34736509

Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Number of subjects: 0
Study: 32063607

Group type: EXPERIMENTAL
Intervention: Home exercise programme for patients with mild to moderate CTS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Home exercise programme for patients without CTS
Number of subjects: 33
Study: 35369022

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 32845715

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (n=2419)
Number of subjects: 4822

Group type: COMPARATOR
Intervention: valsartan (n=2403)
Number of subjects: 4822

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4822

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study: 35080033

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus and Bifidobacterium lactis) for 10 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (potato starch)
Number of subjects: 32
Study: 33555376

Group type: EXPERIMENTAL
Intervention: Surgical occlusion of the middle meningeal artery (soMMA) via a single burr hole during haematoma decompression
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Endovascular embolization of the middle meningeal artery (eMMA)
Number of subjects: 1162
Study: 33827652

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal social and emotional learning (SEL) school provision
Number of subjects: 0
Study: 32822775

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: csDMARDs + GC
Number of subjects: 80
Study: 33413508

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 71
Study: 32045676

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST) via videoconference
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Pain Coping Skills Training (PCST) via in-person
Number of subjects: 178
Study: 35513244

Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control
Number of subjects: 354

Group type: COMPARATOR
Intervention: Validation set
Number of subjects: 354
Study: 33960536

Group type: EXPERIMENTAL
Intervention: Dentist-administered cognitive behavioural therapy (D-CBT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Four Habits Model (FHM) with midazolam sedation
Number of subjects: 96
Study: 35618742

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous serum (AS)
Number of subjects: 0
Study: 33735798

Group type: EXPERIMENTAL
Intervention: PA behavioural modification interventions alongside pulmonary rehabilitation (PR + PA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation alone (PR)
Number of subjects: 48
Study: 34995344

Group type: EXPERIMENTAL
Intervention: Oral azacitidine (Oral‐AZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33781435

Group type: EXPERIMENTAL
Intervention: 1 month primary vaccination interval
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 months primary vaccination interval
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 months primary vaccination interval
Number of subjects: 21
Study: 32124014

Group type: EXPERIMENTAL
Intervention: Presence of massa intermedia (MI)
Number of subjects: 402
Study: 33465455

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 34214454

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 107
Study: 32663278

Group type: EXPERIMENTAL
Intervention: Low dose alcohol (1 standard drink for women, 2 drinks for men)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High dose alcohol (3 standard drinks for women, 4 drinks for men)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 26